Derek joined the company in 2018 as Director of Global Sales
Aptamer Group, the developer of novel Optimer binders to enable innovation in the life sciences industry, today announces the appointment of Derek Smith as Interim Chief Commercial Officer, effective as of 1 January 2023.
Derek joined the company in 2018 as Director of Global Sales and has since become a vital part of the Aptamer team, overseeing the development and implementation of the company’s global sales strategy and securing contracts across all three business divisions, including with a number of major pharmaceutical companies. Prior to joining Aptamer Group, Derek held senior sales positions at various UK healthcare companies.
Dr Arron Tolley, Chief Executive Officer, commented: “Since joining Aptamer in 2018, Derek’s business acumen and commitment to his role have contributed to an impressive increase in our sales and revenue. Derek’s commercial mindset and dedication to the business will stand him in good stead as Interim Chief Commercial Officer. I look forward to working closely with him as we continue to pursue our strategic goals.”
As an increasing number of companies see the need for antibody alternatives, there is a clear opportunity for Aptamer to grow and strengthen its global customer base
Derek Smith, Interim Chief Commercial Officer, said: “I’ve really enjoyed working at Aptamer over the past few years and being a part of its significant commercial progress, including playing a part in the company’s public listing on AIM. As an increasing number of companies see the need for antibody alternatives, there is a clear opportunity for Aptamer to grow and strengthen its global customer base.”